Geiger K, Patil A, Bergman A, Budhathoki C, Heidari O, Lowensen K, Mthimkhulu N, McNabb KC, Mmed NN, Ngozo J, Reynolds N, Farley JE. Exploring HIV disease indicators at MDR-TB treatment initiation in South Africa. Int J Tuberc Lung Dis. 2024 Jan 1;28(1):42-50. doi: 10.5588/ijtld.23.0242. PMID: 38178293.
Archives: Publications
Publications
The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates
Kasaie P, Pennington J, Gupta A, Dowdy DW, Kendall EA. The Impact of Preventive Treatment for Multidrug- and Rifampin-Resistant Tuberculosis Exceeds Trial-Based Estimates. Clin Infect Dis. 2024;78(1):133-143. doi:10.1093/cid/ciad557
Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP
Rohilla A, Singh AK, Koleske B, Srikrishna G, Bishai WR. Structure-based virtual screening and in vitro validation of inhibitors of cyclic dinucleotide phosphodiesterases ENPP1 and CdnP. Microbiol Spectr. 2024;12(1):e0201223. doi:10.1128/spectrum.02012-23
Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis
Tucker EW, Ruiz-Bedoya CA, Mota F, Erice C, Kim J, de Jesus P, Jahdav R, Bahr M, Flavahan K, Chen X, Peloquin CA, Freundlich JS, Jain SK. Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis. Int J Antimicrob Agents. 2024 Jan;63(1):107048. doi: 10.1016/j.ijantimicag.2023.107048. Epub 2023 Dec 5. PMID: 38061419; PMCID: PMC10841818.
Health care providers acceptance of default prescribing of TB preventive treatment for people living with HIV in Malawi: a qualitative study
De Groot LM, Shearer K, Sambani C, Kaonga E, Nyirenda R, Mbendera K, Golub JE, Hoffmann CJ, Mulder C. Health care providers acceptance of default prescribing of TB preventive treatment for people living with HIV in Malawi: a qualitative study. BMC Health Serv Res. 2024 Jan 4;24(1):15. doi: 10.1186/s12913-023-10493-9. PMID: 38178173; PMCID: PMC10768226.
Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes
Paradkar MS, Pradhan NN, Balaji S, Gaikwad SN, Chavan A, Dharmashale SN, Sahasrabudhe T, Lokhande R, Deshmukh SA, Barthwal M, Atre S, Raskar SS, Sawant TU, Gupte AN, Kakrani A, Golub J, Padmapriyadarsini C, Gupta A, Gupte NA, Mave V. Early Microbiologic Markers of Pulmonary Tuberculosis Treatment Outcomes. Ann Am Thorac Soc. 2023 Dec;20(12):1760-1768. doi: 10.1513/AnnalsATS.202302-144OC. PMID: 38038600; PMCID: PMC10704230.
Reducing HIV-associated post-hospital mortality through home-based care in South Africa: a randomized controlled trial
Hoffmann CJ, Shearer K, Kekana B, Kerrigan D, Moloantoa T, Golub JE, Variava E, Martinson NA. Reducing HIV-associated post-hospital mortality through home-based care in South Africa: a randomized controlled trial. Clin Infect Dis. 2023 Dec 5:ciad727. doi: 10.1093/cid/ciad727. Epub ahead of print. PMID: 38051643.
Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis
Parveen, S., Shen, J., Lun, S. et al. Glutamine metabolism inhibition has dual immunomodulatory and antibacterial activities against Mycobacterium tuberculosis. Nat Commun 14, 7427 (2023). https://doi.org/10.1038/s41467-023-43304-0
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Almeida D, Li S-Y, Lee J, Hafkin B, Mdluli K, Fotouhi N, Nuermberger EL. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0078923. doi: 10.1128/aac.00789-23. Epub 2023 Nov 15. PMID: 37966090; PMCID: PMC10720489.
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial
Gupta A, Singh P, Aaron L, et al. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023;7(10):708-717. doi:10.1016/S2352-4642(23)00174-8